You are here: Industry Insights > UCB

News List

UCB, Amgen refile osteoporosis drug Evenity pharmatimes
July 17, 2018
UCB and Amgen have brought their bone-boosting drug Evenity back to US regulators for review, following an initial rejection in July last year.
UCB Announces BRIVIACT Approved by FDA americanpharmaceuticalreview
May 18, 2018
UCB announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the anti-epileptic drug (AED) BRIVIACT (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatme
UCB Announces Briviact (brivaracetam) Now Approved by FDA to Treat Partial-Onset (Focal) Seizures in Pediatric Epilepsy Patients drugs
May 17, 2018
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company’s newest anti-epileptic drug (AED) Briviact (brivaracetam) oral formulations indicated
UCB and Science 37 partner up for virtual, siteless clinical trials fiercebiotech
May 07, 2018
UCB announced it will work with Science 37 to bring clinical trials out of brick-and-mortar research sites and into participants’ homes. By using telemedicine, real-world data and outcomes reported by patients via a mobile device...
UCB to Expand Epilepsy Portfolio with Acquisition of Midazolam Nasal Spray americanpharmaceuticalreview
April 23, 2018
UCB announced an agreement to acquire the rights to Proximagen's Midazolam Nasal Spray (USL261)
UCB to acquire Proximagen’s midazolam nasal spray biospectrumasia
April 23, 2018
UCB estimates that more than 150,000 people with refractory epilepsy also experience ARS.
UCB Acquires Element Genomics americanpharmaceuticalreview
April 09, 2018
UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina
UCB’s Vimpat gets NHS green light in Wales pharmatimes
March 09, 2018
The All Wales Medicines Strategy Group has approved NHS funding for the use of UCB’s Vimpat in children with epilepsy.
UCB, Amgen’s Evenity under review in Europe pharmatimes
January 10, 2018
The European Medicines Agency has accepted UCB and Amgen’s submission seeking approval for use of bone-boosting drug Evenity in post-menopausal women and in men at increased risk of fracture.
EU allows use of UCB’s anti-epileptic Vimpat in children pharmatimes
September 25, 2017
The European Commission has ruled that UCB’s anti-epileptic Vimpat can be used in children.

Previous page 1 2 3 4 5 6 Next page